Novartis gets EC approval for self-administration of Xolair across all indications

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 14, 2018 at 12:52 PM.

  1. #1 cafead, Dec 14, 2018 at 12:52 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via Novartis has secured approval from the European Commission (EC) for Xolair (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.

    article source
     
    Quote

Reply to Thread